Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.63 |
| ▸ | PNMT | P11086 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10695429 | 1.00 | OPRM1 (0.63) | OPRM1OPRL1PNMTKCNH2LMNA | |
| SCHEMBL10695431 | 1.00 | OPRM1 (0.63) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL25378396 | 0.98 | OPRM1 (0.61) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL31263899 | 0.98 | OPRM1 (0.61) | OPRM1OPRL1PNMTKCNH2LMNA | |
| SCHEMBL17782500 | 0.98 | OPRM1 (0.61) | OPRM1OPRL1PNMTKCNH2LMNA | |
| SCHEMBL30581918 | 0.98 | OPRM1 (0.61) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL31263958 | 0.97 | OPRM1 (0.60) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL25378009 | 0.97 | OPRM1 (0.60) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL31263826 | 0.97 | OPRM1 (0.60) | OPRM1OPRL1PNMTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL25378709 | 0.97 | OPRM1 (0.60) | OPRM1OPRL1PNMTKCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| CN-103732589-B | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-30 | — | — | CN | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | disclosed |
| EP-0670318-A2 | Acetamides with analgesic and neuroprotective activity | MERCK PATENT GmbH (DE) | 1995-09-06 | — | — | EP | disclosed |
| US-4753952-A | ANALGESICS | DR. LO. ZAMBELETTI S.P.A. (IT) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | OPRM1 4690/4885OPRL1 3672/4885PNMT 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.